DCVC

Activity from announced rounds

Activity in this selectionOct 20, 2026 · Jul 23, 2026

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
6
Confirmed lead rounds
2
1 roles undisclosed
New companies
5
First participation on record · 1 follow-on
Funding in participating rounds
$1.1B
5 disclosed · full round size, not this investor’s share

By stage

Seed2
Series A2
Series B1
Undisclosed1

By primary sector

AI3
Biotech1
Climate tech1
Hardware1

By country

United States4
United Kingdom2

Rounds

6 in this selection
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
Universal Quantum

Modular trapped-ion quantum computers built by connecting small quantum chips.

>$100MSeries A
Lead
Rainmaker

Rainmaker develops cloud-seeding technology and atmospheric research tools to increase freshwater supply.

$100MSeries B
Participant
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$40MSeed
Lead
Shennon Biotechnologies

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFunding
Participant
Callosum

Software infrastructure allowing AI workloads to run across different chips and models

$100MSeed
Role not disclosed